Browse the corpus

According to the 2023 update of the American Diabetes Association Standards of Medical Care in Diabetes, glyburide and other sulfonylureas are considered viable options for adjunctive therapy, particularly for patients seeking potent agents with a higher chance of attaining glycemic targets. This comprehensive overview of glyburide focuses on its indications, mechanism of action, contraindications, adverse event profile, and monitoring considerations. This activity emphasizes the importance of glyburide as an effective therapeutic option in managing type 2 diabetes for interprofessional team members involved in patient care. Objectives: Identify patients with type 2 diabetes who may be appropriate candidates for glyburide therapy, considering factors such as glycemic control, renal function, and medication history. Screen patients for contraindications and potential risks associated with glyburide, such as renal impairment or a history of hypoglycemia. Assess the effectiveness of glyburide therapy in achieving glycemic control, monitoring blood glucose levels, and adjusting the treatment plan as needed. Collaborate with other healthcare professionals, such as endocrinologists, pharmacists, and diabetes educators, to ensure comprehensive diabetes care and optimize the use of glyburide. Access free multiple choice questions on this topic.

Glyburide toxicity is primarily associated with the risk of severe hypoglycemia due to an excessive dosage, whether it occurs accidentally or intentionally.[9][13] Due to duplicate metabolism involving the CYP2C9 enzyme, drug-drug interactions between glyburide and other sulfonylureas can also potentiate hypoglycemia.[13]

The interprofessional healthcare team, including clinicians and pharmacists, must work together to ensure that the best possible treatment outcomes occur in patients with type 2 diabetes. Consistent monitoring of blood glucose and HbA1C levels is vital in determining treatment success with glyburide. Interprofessional healthcare providers play a crucial role in recognizing the signs and symptoms of hypoglycemia and the frequency of hypoglycemic events while the patient is on glyburide. Strong clinician judgment is necessary at the first signs of hypoglycemia to determine the appropriateness of continuing therapy. If patients with type 2 diabetes are not at their goal HbA1C or blood glucose target levels, glyburide dosages may be increased every 2 to 4 weeks until meeting the desired objective.[9] After initiating glyburide, starting at a low dosage would be considered the safest precaution to mitigate the risk of hypoglycemia and possible weight gain. Nursing plays a crucial role in glyburide therapy management by reporting potential hypoglycemia and educating patients about its signs, which should be promptly communicated to the rest of the healthcare team. Simultaneously, the pharmacist, nurse practitioner, and primary care provider should educate the patient about the importance of positive lifestyle modifications, including smoking cessation, adopting a healthy diet, participating in an exercise program, and maintaining healthy body weight, as ample evidence supports the benefits of lower body weight in achieving better diabetes control.[14] [Level 5] Pharmacists play a critical role in glyburide therapy by verifying appropriate dosing, conducting medication reconciliation, and identifying significant drug-drug interactions, which should be communicated to the rest of the healthcare team for comprehensive patient care. In summary, the effective use of glyburide therapy for glycemic control in patients with type 2 diabetes necessitates an interprofessional team approach involving physicians, specialists, specialty-trained nurses, and pharmacists. This collaborative effort, characterized by open communication and shared decision-making, is essential to achieve optimal patient outcomes and ensure the success of glyburide treatment. [Level 5]